Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding
First Potential Targets Are Spinocerebellar Ataxia And Huntington's Disease
A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.
You may also be interested in...
UCB and Fund+ are supporting a spin out from the renowned VIB research institute and ExeVir Bio CEO Torsten Mummenbrauer told Scrip that the firm's llama antibodies should be in the clinic for COVID-19 possibly by November.
October has been a very good month for Ionis. Following US approval of Tegredi, it has now signed a potentially lucrative deal with existing partner Roche for another antisense drug, this time to tackle advanced dry AMD.
Huntington's disease is one of several genetically defined neurological diseases that are being targeted in a multibillion-dollar collaboration forged between the US's Wave Life Sciences and Japan's Takeda, that could include co-commercialization by the biotech in the US.